Federal regulators have granted clearance to a new diagnostic assistance tool designed to help clinicians more accurately identify autism in children, marking another step forward in the integration of artificial intelligence and biometrics into pediatric healthcare.
The Food and Drug Administration cleared the tool, known as Neurora, this month to inform clinical decisions regarding the diagnosis of children ranging from 18 months to 12 years old. Developed by Argus Cognitive, Inc., the device leverages more than 100 distinct biometrics to assess whether a pediatric patient exhibits behavioral patterns associated with autism spectrum disorder.
The clearance arrives at a critical time for families and healthcare systems grappling with soaring demand for specialized developmental evaluations. According to recent estimates from the Centers for Disease Control and Prevention, autism now affects approximately 1 in 31 children. Despite this high prevalence, many families face extensive waiting lists to have their children evaluated by specialists, with the median age of diagnosis hovering at just under four years old. Tools like Neurora aim to streamline this diagnostic pathway, providing clinicians with objective, quantitative data to support their professional evaluations.
How the Neurora System Works
Unlike some diagnostic devices that require specialized hardware or a disruption to established clinical workflows, Neurora is designed to integrate seamlessly into existing behavioral assessments. Under the system developed by Argus Cognitive, clinicians can upload standard video and audio recordings captured during routine behavioral evaluations directly into the secure Neurora portal.
Once the media is uploaded, the automated tool measures a comprehensive array of behavioral markers, including facial expressions, voice patterns, eye gaze, and other subtle non-verbal cues. It then analyzes these metrics to evaluate how a child’s specific behavioral profile compares against normative data compiled from children both with and without autism.
Crucially, the creators and regulators emphasize that Neurora is not intended to serve as a standalone diagnostic instrument. Instead, the results generated by the software are meant to be considered in conjunction with other clinical findings and professional judgment.
Dr. Attila Meretei, CEO and co-founder of Argus Cognitive, emphasized this collaborative approach in a statement following the FDA clearance.
"We built Neurora to support clinicians evaluating children for autism," Meretei said. "Neurora works inside the assessment clinicians already use, without protocol changes or proprietary hardware, and is fully automated. Our goal is to reinforce every diagnosis with robust, quantitative evidence."
Research and Development Backing
The path to FDA clearance for medical technologies typically involves rigorous testing and independent validation, and Neurora is no exception. Argus Cognitive noted that the development of the tool was supported in part by a competitive National Institutes of Health grant aimed at fostering innovation among entrepreneurs in the medical device sector.
Scientific backing for the technology was further reinforced earlier this year with the publication of a dedicated peer-reviewed study in the journal Frontiers in Psychiatry. According to data from the study, the tool successfully distinguished between children with autism and those without the condition in nearly 78 percent of cases, providing the empirical foundation necessary to pursue regulatory clearance.
Expanding Landscape of Autism Diagnostic Tools
Neurora enters a growing market of FDA-cleared technological aids designed to assist diagnosticians in identifying autism earlier and more reliably in young children. Over the past several years, federal regulators have cleared a select group of digital and device-based solutions aimed at addressing bottlenecks in the evaluation process.
Among these is the EarliPoint Evaluation for ASD, which was previously cleared by the FDA and utilizes specialized eye-tracking technology to analyze a child’s visual engagement and social attention in real time. Similarly, the agency previously cleared Canvas Dx, an algorithm-driven software tool that analyzes information submitted by parents and healthcare providers, alongside video submissions of the child, to help guide clinical decision-making regarding potential diagnoses.
Advocates and healthcare professionals hope that the accumulation of these diagnostic aids will help alleviate the severe backlogs plaguing pediatric developmental clinics nationwide. With earlier identification comes earlier access to evidence-based interventions and therapies, which research consistently shows can significantly improve long-term developmental outcomes for children on the autism spectrum.
As Argus Cognitive prepares for the commercial rollout of Neurora following its recent FDA clearance, the medical community will be watching closely to see how effectively these quantitative biometric insights translate into everyday clinical practice, ultimately helping clinicians bring clarity and timely answers to families navigating the developmental evaluation process.
